These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 6162721)

  • 21. Can thrombolytics prevent post-phlebitic syndrome and thrombo-embolic disease?
    Trübestein G
    Haemostasis; 1986; 16 Suppl 3():38-50. PubMed ID: 3770543
    [No Abstract]   [Full Text] [Related]  

  • 22. Thrombolytic therapy: an introduction and review.
    Thiagarajan D
    J Kans Med Soc; 1980 Jun; 81(6):292-3. PubMed ID: 6995538
    [No Abstract]   [Full Text] [Related]  

  • 23. Production of the modified form of human plasminogen by alpha 2-macroglobulin-plasmin complexes.
    Yamamoto J; Okamoto U; Morita S; Asada N; Yamaoka M
    Jpn J Physiol; 1985; 35(6):1013-21. PubMed ID: 2422420
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Proteinase inhibitors and fibrinogen split products in patients with malignant diseases (author's transl)].
    Schwarz HP; Aiginger P; Kuzmits R
    Acta Med Austriaca; 1981; 8(1):22-5. PubMed ID: 6165218
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Components of the kallikrein-kinin-system in patients with ARDS.
    Fuhrer G; Heller W; Junginger W; Gröber O; Roth K
    Prog Clin Biol Res; 1989; 308():737-42. PubMed ID: 2476827
    [No Abstract]   [Full Text] [Related]  

  • 26. Thrombolytic therapy: controversial aspects.
    Gaffy MM; Lollar P; Goldsmith J
    J Iowa Med Soc; 1982 Jul; 72(7):294-6. PubMed ID: 6750010
    [No Abstract]   [Full Text] [Related]  

  • 27. Studies on the activation mechanism of fibrinolytic enzyme system in plasma by human pancreatic elastase.
    Toki N; Takasugi S; Ishizu K; Sato H; Sumi H
    Thromb Haemost; 1982 Feb; 47(1):8-13. PubMed ID: 6176043
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Streptokinase and urokinase.
    Med Lett Drugs Ther; 1978 Apr; 20(8):37-8. PubMed ID: 634226
    [No Abstract]   [Full Text] [Related]  

  • 29. Thrombolytic treatment of venous thromboembolism.
    Gurewich V
    Vasc Surg; 1977; 11(6):341-2. PubMed ID: 616147
    [No Abstract]   [Full Text] [Related]  

  • 30. Pharmacokinetics and pharmacodynamics of saruplase, an unglycosylated single-chain urokinase-type plasminogen activator, in patients with acute myocardial infarction.
    Koster RW; Cohen AF; Hopkins GR; Beier H; Günzler WA; van der Wouw PA
    Thromb Haemost; 1994 Nov; 72(5):740-4. PubMed ID: 7534946
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison of the relative fibrinogenolytic, fibrinolytic and thrombolytic properties of tissue plasminogen activator and urokinase in vitro.
    Matsuo O; Rijken DC; Collen D
    Thromb Haemost; 1981 Jun; 45(3):225-9. PubMed ID: 7025339
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Interaction of SK-human plasmin, SK-dog plasmin complexes with alpha 2-antiplasmin and alpha 2-macroglobulin.
    Reddy KN; Cercek B; Lew AS; Ganz W
    Thromb Res; 1986 Mar; 41(5):671-80. PubMed ID: 2421434
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Experimental aspects of the therapeutic action of urokinase in thromboembolic states].
    Danilenko MV; Stasiuk NS
    Biull Eksp Biol Med; 1981 Mar; 91(3):293-5. PubMed ID: 7018613
    [No Abstract]   [Full Text] [Related]  

  • 34. [When is fibrinolytic therapy indicated?].
    Woitinas F
    Med Klin; 1980 Feb; 75(3):98-107. PubMed ID: 6990218
    [No Abstract]   [Full Text] [Related]  

  • 35. [The changes of alpha 2-plasmin inhibitor, and notably urokinase activities in blood measured by synthetic chromogenic substrates S-2444 after urokinase administration].
    Itoh Y; Tsuji K; Tanaka N; Yamada M; Nakanishi M; Ishihara M; Kobayashi M
    Nihon Sanka Fujinka Gakkai Zasshi; 1983 Jan; 35(1):68-76. PubMed ID: 6338134
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Complete inhibition of fibrinolysis by sustained carboxypeptidase B activity: the role and requirement of plasmin inhibitors.
    Walker JB; Bajzar L
    J Thromb Haemost; 2007 Jun; 5(6):1257-64. PubMed ID: 17389009
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Acceleration of plasma clot lysis by an antibody to alpha 2-antiplasmin.
    Reed GL; Matsueda GR; Haber E
    Trans Assoc Am Physicians; 1988; 101():250-6. PubMed ID: 2480017
    [No Abstract]   [Full Text] [Related]  

  • 38. Protease inhibitor and gastric cancer.
    Tsumoto S; Oyabu H; Kageyama T
    Bull Osaka Med Sch; 1983 Jul; 29(1):18-26. PubMed ID: 6204707
    [No Abstract]   [Full Text] [Related]  

  • 39. Interaction of plasmin with alpha 2-macroglobulin and alpha 2-antiplasmin in the presence and absence of tranexamic acid.
    Takada A; Takada Y
    Thromb Res; 1980 Apr 1-15; 18(1-2):237-46. PubMed ID: 6157220
    [No Abstract]   [Full Text] [Related]  

  • 40. Thrombolytic therapy: Current status.
    Fratantoni JC; Ness P; Simon TL
    N Engl J Med; 1975 Nov; 293(21):1073-8. PubMed ID: 1178024
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.